Navigation Links
Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark
Date:6/29/2015

NEW YORK, June 29, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that patient enrollment in its proof-of-concept pharmacokinetic study with novel formulations of oral, enteric-coated buprenorphine (collectively BuTab, or REL-1028) being developed for both chronic pain and opioid dependence indications has reached the halfway point. Consistent with prior guidance, the company anticipates reporting top-line results in the second half of 2015.

"The halfway point of our proof-of-concept study marks another important milestone in our efforts to advance an oral formulation of BuTab that will compare favorably with currently marketed formulations of buprenorphine," stated Sergio Traversa, CEO of Relmada Therapeutics.  "As a traditional tablet taken by mouth and passing down the intestinal tract where it will ultimately be absorbed, BuTab would represent an important advance in patient care and a significant commercial opportunity for Relmada. We look forward to reporting results from this study during the second half of 2015. "

The clinical study is designed to assess the safety, tolerability, and pharmacokinetics of BuTab in healthy subjects. Based on the underlying scientific rationale and the company's previously conducted successful preclinical work, the key objective of this study is to assess if buprenorphine can be delivered orally and reach safe and effective blood levels through the gastrointestinal route of administration. There are currently no commercially available oral formulations of buprenorphine that result in gastro-intestinal absorption. The data generated by this study will inform the design of subsequent clinical pharmacology studies for opioid dependence and potential regulatory filing for this indication along with the design of a Phase 3 study in chronic pain under the abbreviated 505(b)(2) regulatory pathway.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.

Forward-Looking Statements

This news release contains "forward-looking statements."  These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements.  The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected.  Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact
Investor Contact:
Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Tel: 212-702-7169
mbecker@relmada.com

Media Contact:
David Salisbury
Berry & Company Public Relations
Tel: 212-253-8881
dsalisbury@berrypr.com

Logo - http://photos.prnewswire.com/prnh/20150113/168770LOGO


'/>"/>
SOURCE Relmada Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. DC Devices Completes Enrollment In Clinical Trial Of The First Transcatheter Device To Treat Diastolic Heart Failure; Announces Name Change To Corvia Medical
2. Astellas And Medivation Announce Enrollment Of The First Patients In Advanced Prostate Cancer Outcomes Registry
3. ForSight VISION5s Clinical Data Demonstrating 6-Month IOP-Lowering from a Single Dose Presented at World Glaucoma Congress; Company Completes Enrollment of Phase 2 Dose-Ranging Study
4. ICC Cohort Of Delcaths Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open For Enrollment
5. Enrollment In Mast Therapeutics Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark
6. AirXpanders Completes Enrollment in XPAND US Pivotal Trial
7. CSSi Quadruples Screening Activity and Speeds Enrollment for Pediatric Dermatology Study
8. Medicare Advantage Enrollment Reaches 17 Million According to Mark Farrah Associates
9. CREDIT II Stent Trial Completes Enrollment
10. Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States
11. Lexicon Pharmaceuticals Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Telotristat Etiprate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The ... to promote standards of excellence for the field of eating disorders, announces the ... – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
Breaking Medicine News(10 mins):